Big Pharma Earnings, FDA Wins Drive Healthcare Rally

Amgen ($AMGN) reported second quarter 2026 revenue of $10.05 billion and net income of $2.38 billion, delivering growth driven by key products including Repatha and UPLIZNA. For the first half of 2026, $AMGN posted revenue of $18.67 billion and net income of $4.19 billion, with diluted earnings per share from continuing operations of $7.71. The company raised its full-year 2026 guidance following the strong performance. Revenue surged past the $10 billion quarterly mark with growth attributed to the expanding contributions from its cardiovascular and rare disease franchises.

Gilead Sciences ($GILD) reported second-quarter 2026 base business sales growth to $7.6 billion, representing its strongest Q2 base business growth in three years. The company's PrEP (pre-exposure prophylaxis) sales doubled to $1 billion, underscoring rapid uptake in HIV prevention. $GILD raised its full-year HIV guidance and highlighted strong performance from Yeztugo and Trodelvy in its oncology portfolio, though the stock slipped following the earnings release as full-year guidance disappointed investors despite the Q2 beat. Acquisition-related charges offset some of the operational momentum, creating an EPS drag that weighed on sentiment.

Eli Lilly ($LLY) gained FDA Breakthrough Therapy designation for its investigational drug olomorasib in KRAS G12C-mutant advanced pancreatic cancer, supported by positive Phase 3 trial data. If approved, olomorasib would represent an expansion of $LLY's oncology franchise into a difficult-to-treat pancreatic cancer subset. AbbVie ($ABBV) announced that the FDA accepted for review a supplemental Biologics License Application for BOTOX Cosmetic to treat masseter muscle prominence, which if cleared would mark the first neurotoxin approved in the U.S. for this aesthetic indication. These regulatory milestones highlight ongoing efforts by major biopharma companies to expand labeled indications and address unmet medical needs across oncology and aesthetics.

Pfizer ($PFE), Merck ($MRK), and $AMGN are doubling down on cancer franchises, fueling retail partnership and buyout speculation around smaller oncology-focused biotechs. The focus on oncology dealmaking aligns with Big Pharma's strategic push to replace revenue from maturing blockbusters and address patent cliff exposure. Takeover buzz around SLS and IBRX intensified as these names align with the cancer investment themes driving current M&A activity. No specific transaction terms or valuations were disclosed, but the speculation reflects heightened investor attention on potential consolidation in the biotech oncology space.

Johnson & Johnson ($JNJ) announced that longtime executive Jennifer Taubert retired as Executive Vice President, Worldwide Chairman, Innovative Medicine, with experienced biopharmaceutical leader Tom Cavanaugh set to succeed her. The leadership change comes as $JNJ posted a year-to-date share price return of 22.95%, a 90-day return of 13.49%, and a one-year total shareholder return of 53.04%. Despite the strong run, valuation analysis suggests the stock could be overvalued by as much as 10% following the transition. Separately, commentary on $JNJ highlighted an $85 billion capital return to shareholders, though the stock's performance has lagged relative to total cash distributions over the period.

Investor focus will remain on upcoming FDA regulatory decisions, including the potential approval of $ABBV's BOTOX Cosmetic for masseter muscle prominence and further development updates on $LLY's olomorasib in pancreatic cancer. Earnings season continues to shape sentiment, with investors parsing guidance revisions and pipeline progress from major biopharma names. M&A speculation in oncology is likely to persist as Big Pharma seeks to bolster cancer portfolios ahead of anticipated patent expirations, while valuation debates around high-performing names like $JNJ and $AMGN will influence positioning decisions in the weeks ahead.